Exact Sciences Precision Oncology

Molecular Residual Disease (MRD) can be shed by cancer cells into the bloodstream in the form of circulating tumor DNA (ctDNA). Because ctDNA carries genetic mutations and alterations unique to the tumor, it is a valuable biomarker for cancer detection and monitoring, even helping detect cancer recurrence at an early stage before symptoms appear.* *CMS, Medicare Coverage Database. MRD Testing for Cancer. https:// www.cms.gov/

Looking forward to seeing you in Boston! Stop by booth 547 to learn more about the OncoExTra? test. #USCAP25 #USCAP2025 #OncoExTra?

Lingering cancer cell fragments in the blood, specifically circulating tumor DNA (ctDNA), may indicate molecular residual disease (MRD) is present in the body after surgery or treatment. Identifying even minuscule fragments, MRD testing is an important complement to standard of care methods, supporting proactive cancer care for patients with solid tumors. #MRD #CancerCare #SolidTumor

When treating patients with solid tumors, turn unknowns into answers with the OncoExTra? test. The ultra-comprehensive genomic profiling test allows you to both sequence DNA+RNA and add on pre-selected tumor-specific IHC panels in a single test order, so you can make meaningful decisions for your patients with fewer unknowns.*? Get more info on OncoExTra?: https://lnkd.in/ev_MyZ2c *IHC testing not currently available in NY State ?White et al. Oncotarget. 2021;12:726-739 #Healthcare #Oncology #PrecisionMedicine #Cancer

In a recent article published by Oncology Times, Dr Rick Baehner examines the value of ultra-comprehensive genomic profiling. Tests such as the OncoExTra? test from Exact Sciences include both DNA and RNA sequencing, to help inform treatment decisions regarding targeted therapies for solid tumors. The OncoExTra test uncovers clinically actionable variants in over 90% of patients with colorectal, lung, bladder, and breast cancers.* Read the article: https://bit.ly/43f0rOq #RNA #Oncology #GenomicProfiling *White et al. Oncotarget. 2021;12(8):726-739

Calling all NCCN 2025 Annual Conference attendees! Did you know that the Oncotype DX Breast Recurrence Score? test is the only test proven to predict likelihood of chemotherapy benefit for patients with early-stage HR+, HER2- breast cancer?* Find out if your patient is eligible. Explore: https://bit.ly/4bqdVZF #NCCN2025 #BreastCancer #Oncology #GenomicProfiling *Albain et al. Lancet Oncol. 2010;11(1):55-65; Paik et al. J Clin Oncol. 2006;24(23):3726-3734

Will a patient newly diagnosed with early-stage HR+, HER2- breast cancer benefit from chemotherapy? The Oncotype DX Breast Recurrence Score? test reveals important data.* It also helps to understand hereditary risk and the value of alternative treatment options or a need for increased surveillance. The Riskguard? test holds insights. Consider pairing the tests. Explore https://bit.ly/4bfw1gR #BreastCancer #OncologyDiagnostics #PersonalizedCancerTreatment *Paik et al. J Clin Oncol. 2006;24(23):3726-3734; Albain et al. Lancet Oncol. 2010;11(1):55-65

At every phase of cancer care there’s a critical question. Is cancer present? What’s the right treatment? Are there personalized options? Our comprehensive portfolio of oncology tests can help provide the critical insights you need. These tests help guide personalized treatment decisions from cancer screening to advanced therapy selection. Explore the portfolio: https://bit.ly/4bfw1gR #OncologyDiagnostics #AdvancedTherapy #CancerTest

We’re excited to attend the #MiamiBreast Meeting again this year! Join us at booth 55 to learn more about the Oncotype DX Breast Recurrence Score? test from Exact Sciences. #OncotypeDX #PrecisionOncology #MBCC25 #MBCC2025 #MiamiBreastCancerConference #MiamiBreast #BreastCancer #Cancer #Oncology #Chemotherapy #PrecisionOncology #PrecisionMedicine #CancerResearch #CancerTreatment

Oncologists have many responsibilities and little time between explaining diagnoses, making treatment decisions, caring for patients, and so much more. In a new Oncology Times article, Christy Russell, MD, explains how the OncoExTra? test offers busy oncologists the clear, actionable guidance they need to personalize treatment decisions efficiently, so they can turn unknowns into answers. Read the full article: https://bit.ly/41oqM9X #Healthcare #Oncology #PrecisionMedicine #CancerCare